OncoVerity eyes cusatuzumab development in AML after licensing rights

On March 27, OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, which came from both Argenx and the venture of UCHealth and the University License Equity Holdings.